SCHEMBL25419563

SCHEMBL25419563

CC(C)(C)OC(=O)N1CCN(c2nc(C(=O)c3ccccc3)co2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CKS1B P61024 2/20 0.49
▸ SKP1 P63208 2/20 0.49
▸ SKP2 Q13309 2/20 0.49
▸ GBA1 P04062 2/20 0.46
▸ ACHE P22303 1/20 0.45
▸ GPR119 Q8TDV5 2/20 0.45
▸ ABCB1 P08183 2/20 0.44
▸ ABCG2 Q9UNQ0 1/20 0.44
▸ ADORA2A P29274 2/20 0.44
▸ ADORA1 P30542 1/20 0.44
▸ PTPN11 Q06124 1/20 0.44
▸ KDM4E B2RXH2 1/20 0.43
▸ PKM P14618 1/20 0.43
▸ KIT P10721 1/20 0.42
▸ SMARCA2 P51531 1/20 0.42
▸ SMARCA4 P51532 1/20 0.42
▸ PBRM1 Q86U86 1/20 0.42
▸ ESRRB O95718 1/20 0.42
▸ ESR1 P03372 1/20 0.42
▸ ESRRA P11474 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17373792 0.86 CKS1B (0.46) CKS1BSKP1SKP2GBA1ACHE
SCHEMBL31197670 0.82 CKS1B (0.50) CKS1BSKP1SKP2GBA1ACHE
SCHEMBL3764612 0.82 CKS1B (0.56) CKS1BSKP1SKP2GBA1ACHE
SCHEMBL26146349 0.79 ACHE (0.52) CKS1BSKP1SKP2GBA1ACHE
SCHEMBL17373778 0.79 CKS1B (0.43) CKS1BSKP1SKP2ACHEGPR119
SCHEMBL25177949 0.79 CKS1B (0.53) CKS1BSKP1SKP2GBA1ACHE
SCHEMBL14990872 0.78 CKS1B (0.46) CKS1BSKP1SKP2ACHEGPR119
SCHEMBL26146347 0.78 CKS1B (0.47) CKS1BSKP1SKP2GBA1ACHE
SCHEMBL25418079 0.78 MAPT (0.41) CKS1BSKP1SKP2ACHEGPR119
SCHEMBL31197676 0.77 CKS1B (0.45) CKS1BSKP1SKP2GPR119ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250129067-A1 PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF PROGENTOS THERAPEUTICS, INC. (US) 2025-04-24 — — US disclosed
EP-4430047-A1 PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF Progentos Therapeutics, Inc. (US) 2024-09-18 — — EP disclosed
WO-2023081923-A1 PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF Frequency Therapeutics, Inc. (US) 2023-05-11 — — WO disclosed
WO-2023081923-A1 PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF Frequency Therapeutics, Inc. (US) 2023-05-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250129067-A1 PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF PDGFRB, PDGFRA, PDGFA CKS1B 757/4885SKP1 3819/4885SKP2 1642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback